-transparent.png){kind=logo}
Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus. 2021
Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell School of Medicine, New York Presbyterian, New York, NY.
Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after initiation of ibalizumab therapy.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
April 2024,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
June 2006,
Zhonghua nei ke za zhi,
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
April 2018,
The Medical letter on drugs and therapeutics,
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
February 2000,
The American journal of medicine,
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
March 2005,
European journal of haematology,
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
September 1990,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
November 1998,
Kekkaku : [Tuberculosis],
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
November 2015,
Liver international : official journal of the International Association for the Study of the Liver,
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
August 2018,
The New England journal of medicine,
Alyson Kaplan, and
Elliott DeHaan, and
Charles Maltz
February 2014,
The British journal of dermatology,
